Literature DB >> 18509354

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.

A Agarwal, C A Eide, A Harlow, A S Corbin, M J Mauro, B J Druker, C L Corless, M C Heinrich, M W Deininger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18509354     DOI： 10.1038/leu.2008.124

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R.

Authors:  Zhi Sheng; Shu-Zong Wang; Michael R Green
Journal:  EMBO J       Date:  2009-02-19       Impact factor: 11.598

Review 2.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

3.  Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.

Authors:  Philip A Beer; David J H F Knapp; Paul H Miller; Nagarajan Kannan; Ivan Sloma; Kathy Heel; Sonja Babovic; Elizabeth Bulaeva; Gabrielle Rabu; Jefferson Terry; Brian J Druker; Marc M Loriaux; Keith R Loeb; Jerald P Radich; Wendy N Erber; Connie J Eaves
Journal:  Blood       Date:  2014-11-04       Impact factor: 22.113

Review 4.  Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Authors:  Christopher A Eide; Thomas O'Hare
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

5.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

Review 6.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

7.  ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Authors:  Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

Review 8.  Clinical relevance of KRAS in human cancers.

Authors:  Sylwia Jancík; Jirí Drábek; Danuta Radzioch; Marián Hajdúch
Journal:  J Biomed Biotechnol       Date:  2010-06-07

Review 9.  Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Authors:  Mohamed A M Ali
Journal:  Mol Diagn Ther       Date:  2016-08       Impact factor: 4.074

10.  The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.

Authors:  Slah Ouerhani; Karim Bougatef; Ismail Soltani; Amel Ben Ammar Elgaaied; Salem Abbes; Samia Menif
Journal:  Mol Biol Rep       Date:  2013-05-03       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.